Agios Pharmaceuticals (AGIO-$43.35) moved substantially
higher in price last month after reporting Phase 1 data demonstrating that its
cancer metabolism drug AG-221, a first-in-class inhibitor of IDH2 mutations,
generated promising clinical activity, including complete remissions in several
patients whose blood cancers harbored the IDH2 mutation.
What has investors excited is that
in addition to being well-tolerated, a “substantial” reduction of plasma 2-HG
was achieved: Called an “oncometabolite” for its role in cancer metabolism, the
metabolite 2-hydroxygluturate (2HG) is a by-product of the mutated IDH2 gene.
The initial findings support the theory that inhibiting mutant forms of IDH2
suppresses the growth of these 2HG-producing tumor cells.
Investors are making the quantum leap – based on a small
safety/dosing trial – that curtailing 2-HG supply will normalize gene
expression….
Continue reading at PropThink: AGIOS,
OF 2013 IPO CLASS, IMPRESSES WITH EARLY ONCOLOGY ASSET
Editor
David J Phillips does not hold a financial interest in any stocks mentioned in
this article. The 10Q Detective has a Full Disclosure Policy.
No comments:
Post a Comment